Fatima Cardoso

Jan 23, 2025 | nature.com | Fresia Pareja |Rohit Bhargava |Virginia F. Borges |Edi Brogi |Fatima Cardoso |Christine Desmedt | +16 more

AbstractSpecial histologic subtypes of breast cancer (BC) exhibit unique phenotypes and molecular profiles with diagnostic and therapeutic implications, often differing in behavior and clinical trajectory from common BC forms. Novel methodologies, such as artificial intelligence may improve classification. Genetic predisposition plays roles in a subset of cases. Uncommon BC presentations like male, inflammatory and pregnancy-related BC pose challenges.

Jan 21, 2025 | nature.com | Fatima Cardoso |Heather L. McArthur |Javier Cortés |Nadia Harbeck |Melinda L. Telli |David W. Cescon | +3 more

AbstractAddition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab improved outcomes in patients with high-risk, early-stage, triple-negative breast cancer. However, whether the addition of neoadjuvant pembrolizumab to chemotherapy would improve outcomes in high-risk, early-stage, estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2−) breast cancer remains unclear.

Dec 5, 2024 | nature.com | Fatima Cardoso

AbstractAdditional therapies are needed to improve outcomes in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative breast cancer. Research on the potential role of immunotherapy, particularly programmed cell death protein 1/programmed cell death ligand 1 inhibitors, is rapidly expanding in both the early and metastatic settings with some preliminary evidence suggesting benefit when used as part of combination therapy.

Jul 5, 2024 | myoncologia.pt | Fatima Cardoso

Entrada Entrevistas “Precisamos de manter a via HER2+ bloqueada” nos doentes com cancro da mama HER2+ Entrevistas 05 Jul. 2024 A presidente da ABC Global Alliance Fátima Cardoso foi convidada para ser uma das oradoras do evento, organizado pela Pfizer, no qual apresentou o tema “Gestão otimizada da doença HER2+”. Esta reunião promoveu também a discussão entre pares da utilização terapêutica do inibidor das tirosinas cinases seletivo para o HER2+. Assista às declarações da oncologista....

May 30, 2024 | medscape.com | Fatima Cardoso |Priscilla K Brastianos |Laura A. Huppert |Orit Kaidar-Person

Authors and Disclosures Fatima Cardoso, MD Director, Breast Unit, Champalimaud Clinical Centre, Lisbon, Portugal Disclosure: Fatima Cardoso, MD, has disclosed the following relevant financial relationships: Personal financial interest in form of consultancy role for: Amgen; Astellas/Medivation; AstraZeneca; Celgene; Daiichi-Sankyo; Eisai; GE Oncology; Genentech; Gilead; GlaxoSmithKline; IQVIA; Macrogenics; Medscape; Merck-Sharp; Merus BV; Mylan; Mundipharma; Novartis; Pfizer; Pierre-Fabre;...